Ann Meulemans holds a PhD in Science from the University of Antwerp (Biology/Pharmacology) and a Master in Management from UA and Middle Management MBA from Vlerick Business School.
She has 25 years’ experience in drug discovery/drug development & general/strategic project management. As compound development leader (JNJ), VP early development (Movetis, Shire), and several C-level positions ad interim (small biotechs), she guided >15 products in different disease area from target identification to human POC (Phase 2B).
Author of > 100 abstracts, patents and peer reviewed articles.
Past and current board member of Center of Medical Innovation, several start up biotechs, H. Hart Hospital of Mol.
Currently she is managing partner and co-founder of 2Bridge CVBA and co-founder of Octimet Oncology.
Building teams around people and assets to bring the best out of both has become a second nature for her.